Table 1.
The demographic characteristics of patients in this study.
| Patient Demographics | CMV reactivation n=41 (%) |
No reactivation n=25 (%) |
|---|---|---|
| Age range | 20—70 years (median: 59 years) |
26—72 years (median: 57.5 years) |
| Reactivation days after transplant | 52 ± 5 (median: day 43) | – |
| Reactivation day range | 10—125 days | – |
| CMV serostatus (Recipient/Donor) | ||
| R+/D+ R+/D- R-/D- R+/D equivocal |
23 (56.1) 15 (36.6) 2 (4.9) 1 (2.4) |
8 (32.0) 2 (8.0) 15 (60.0) - |
| Sex | ||
| Male Female |
24 (58.5) 17 (41.5) |
14 (56.0) 11 (44.0) |
| Donor type | ||
| Matched related donor (sibling) Mismatched related donor (haplo) Matched unrelated donor (10/10) Mismatched unrelated donor (9/10) Double umbilical cord |
12 (29.2) 2 (5.0) 23 (56.0) 1 (2.5) 3 (7.5) |
8 (32.0) - 17 (68.0) - - |
| Diagnosis | ||
| Myeloid (AML/MDS) Lymphoid (ALL/NHL/HL) Others |
28 (70.0) 10 (25.0) 2 (5.0) |
15 (60.0) 8 (32.0) 2 (8.0) |
| Relapse incidence | ||
| Relapse Non-relapse |
10 (24.4) 31 (75.6) |
10 (40.0) 15 (60.0) |
| Conditioning | ||
| Myeloablative Reduced intensity |
6 (15) 35 (85) |
6 (24) 19 (76) |
| T cell depletion | ||
| Anti thymocyte globulin Alemtuzumab Post transplant cyclophosphamide none |
17 (41.5) 19 (46.0) 2 (5.0) 3 (7.5) |
11 (44.0) 12 (48.0) - 2 (8.0) |
| CMV episodes | ||
| Single viral episode Multiple viral episodes |
22 (53.7) 19 (46.3) |
- - |